CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 96 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 1
  • Egg donors
Key exclusion· 1
  • Donors with important diseases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00848185
NCT00848185N/ACompleted

Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence

IVI Madrid·observational·Posted Feb 20, 2009·Updated Jun 26, 2018

In Brief

An observational study for Vascular Endothelial Growth Factor Overexpression. Completed, enrolled 96 participants.

Detailed Summary

Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 20, 2009
Enrollment StartJun 1, 2008
Primary CompletionFeb 1, 2009
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.4 years ago